Novak R, Kern J, Fister H, Trnski D, Dimanovski J, Kraus O
Urology Clinic, Clinical Hospital Dr. M. Stojanovic, Zagreb, Yugoslavia.
Eur Urol. 1988;14(5):367-70. doi: 10.1159/000472984.
409 cases of superficial bladder carcinoma (pTa, pTi, Tis) are reported. They are divided into three groups: 171 patients treated by TUR alone, 124 treated by TUR and local thio-TEPA, and 114 patients treated by TUR and BCG vaccine locally. It was found that the frequency of recurrence fell by 56.7, 41.9 and 26.3%, while the progression of the illness declined correspondingly by 19.8, 16.9 and 11.4%. In other words, in terms of recurrence and progression, the poorest results were found for the group treated by TUR only, and the best results were found with the TUR and BCG group.
报告了409例浅表性膀胱癌（pTa、pTi、Tis）。它们被分为三组：仅接受经尿道膀胱肿瘤切除术（TUR）治疗的171例患者，接受TUR和局部噻替派治疗的124例患者，以及接受TUR和局部卡介苗（BCG）疫苗治疗的114例患者。结果发现，复发率分别下降了56.7%、41.9%和26.3%，而疾病进展相应地下降了19.8%、16.9%和11.4%。换句话说，就复发和进展而言，仅接受TUR治疗的组效果最差，而TUR联合BCG组效果最佳。
